Abstract 5518: Use of antihypertensive drugs and the risk of cancer, findings of a population-based cohort study in Shanghai

Abstract

Abstract Background: The widespread use of antihypertensive drugs has raised concerns on whether the use increases the risk of cancer. Although multiple studies have addressed this issue, it remains unclear if hypertension patients who are on antihypertensive medications are at higher risk for cancer. Methods: Between 2013 and 2017, we enrolled 101,370 individuals with hypertension from community healthcare centers in Changning Shanghai, followed through December 31, 2019. Drug administration was defined as the class and number of ever use the major antihypertensives. The main outcomes included the incidences of all cancer and major types of cancer in Shanghai (lung, colorectum, thyroid, and stomach). Results: During a mean follow-up of 5.1 (SD 1.3) years, 4970 cancer cases were newly diagnosed in the cohort. CCBs were the most frequently used antihypertensives which were associated with a moderately increased risk of all cancer (hazard ratio, HR: 1.11, 95% CI: 1.05-1.18). The second commonly used drug ARBs were also associated with increased risk of all cancer (HR: 1.10, 95%CI: 1.03-1.17) as well as lung and thyroid cancers (HR: 1.21, 95%CI: 1.05-1.39; HR: 1.66, 95%CI: 1.22-2.27, respectively). No cancer association was found with other antihypertensives. Individuals who use more than one class of antihypertensives had a higher risk of all cancer, and a possible dose-response relationship was suggested. Conclusions: Use of ARBs or CCBs may be associated with an increased risk of cancer. Taking more than one class of antihypertensives appeared to have a higher risk for cancer. Citation Format: Suna Wang, Li Xie, Ying Qian, Jie Wang, Guanglu Zhang, Lei Li, Weituo Zhang, Herbert Yu, Wensui Zhao, Biyun Qian. Use of antihypertensive drugs and the risk of cancer, findings of a population-based cohort study in Shanghai. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 5518.